Dr. Perales on the Future of CAR T-Cell Therapy in DLBCL and Follicular Lymphoma

Miguel-Angel Perales, MD
Published: Tuesday, Dec 10, 2019



Miguel-Angel Perales, MD, deputy chief, Adult Bone Marrow Transplant Service, director, Adult Bone Marrow Transplantation Fellowship Program, Memorial Sloan Kettering Cancer Center, discusses the future of CAR T-cell therapy in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma.

There is potential to move CAR T cells earlier in treatment of patients with DLBCL and follicular lymphoma, says Perales. Studies have examined earlier CAR T-cell therapy in mantle cell lymphoma, while other studies looked at combining CAR T cells with checkpoint inhibitors. The results of those studies still need to be released, says Perales.

The results of CAR T-cell therapy in follicular lymphoma are promising, he adds. A study from the University of Pennsylvania looked at a small group of 14 patients and showed positive survival curves with this approach. Another study examined a different small group of patients with follicular lymphoma versus patients with transformed follicular lymphoma. Results from the study showed that patients with follicular lymphoma responded better to CAR T-cell therapy than those with transformed follicular lymphoma. These results were similar to that of the study conducted at the University of Pennsylvania, concludes Perales.
SELECTED
LANGUAGE


Miguel-Angel Perales, MD, deputy chief, Adult Bone Marrow Transplant Service, director, Adult Bone Marrow Transplantation Fellowship Program, Memorial Sloan Kettering Cancer Center, discusses the future of CAR T-cell therapy in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma.

There is potential to move CAR T cells earlier in treatment of patients with DLBCL and follicular lymphoma, says Perales. Studies have examined earlier CAR T-cell therapy in mantle cell lymphoma, while other studies looked at combining CAR T cells with checkpoint inhibitors. The results of those studies still need to be released, says Perales.

The results of CAR T-cell therapy in follicular lymphoma are promising, he adds. A study from the University of Pennsylvania looked at a small group of 14 patients and showed positive survival curves with this approach. Another study examined a different small group of patients with follicular lymphoma versus patients with transformed follicular lymphoma. Results from the study showed that patients with follicular lymphoma responded better to CAR T-cell therapy than those with transformed follicular lymphoma. These results were similar to that of the study conducted at the University of Pennsylvania, concludes Perales.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x